Tg Therapeutics, Inc.
Clinical trials sponsored by Tg Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing treatments for B-cell malignancies and autoimmune diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Ublituximab shows promise for Long-Term MS control in large extension trial
Disease control OngoingThis study is a long-term follow-up for people with relapsing multiple sclerosis who previously completed a ublituximab trial. It aims to see if the drug remains safe and effective over time. About 1100 participants will receive ublituximab infusions, and researchers will track r…
Phase: PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
MS patients may soon get a shot instead of an IV drip
Disease control OngoingThis phase 3 trial tests whether a shot (subcutaneous) of ublituximab works as well as the standard IV infusion for people with relapsing multiple sclerosis. About 360 participants are enrolled. The main goal is to compare drug levels in the blood over 24 weeks, along with safety…
Phase: PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC